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ABSTRACT Induction of a type 2 cellular response in
the white adipose tissue leads to weight loss and improves
glucose homeostasis in obese animals. Injection of obese
mice with recombinant helminth-derived Schistosomamansoni
egg-derived v1 (v1), a potent inducer of type 2 acti-
vation, improves metabolic status involving a mechanism
reliant upon release of the type 2 initiator cytokine IL-33.
IL-33 initiates the accumulation of group 2 innate lym-
phoid cells (ILC2s), eosinophils, and alternatively acti-
vated macrophages in the adipose tissue. IL-33 release
from cells in the adipose tissue is mediated by the RNase
activity of v1; however, the ability of v1 to improve met-
abolic status is reliant upon effective binding of v1 to
CD206. We demonstrate a novel mechanism for RNase-
mediated release of IL-33 inducing ILC2-dependent im-
provements in the metabolic status of obese animals.—
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Obesity is associated with a low-grade proinflammatory state,
with a central role for immune cells that infiltrate the adipose
tissue contributing to localized and systemic inflammation
and promoting insulin resistance and the development of
metabolic syndrome (1, 2). The extent of obesity-related
metabolicdysfunctiondirectlycorrelateswith therecruitment
of proinflammatory cells, M1 classically activated macro-
phages (CAMs), and CD8+ T and CD4+ T helper (Th)-1 cells
into the adipose tissue. Conversely, in lean individuals, the
adipose tissue is populated with eosinophils, regulatory T
(Treg)cells,NKTcells,group2 innate lymphoidcells (ILC2s),
and M2 alternatively activated macrophages (AAMs), which
promote insulin sensitivity andmetabolic homeostasis (3–5).
In experiments on obese mice, the artificial generation
of a type 2 environment (e.g., by infecting with type 2-
inducing helminths such as Nippostrongylus brasiliensis and
Schistosoma mansoni) has been shown to induce sustained
weight loss and improvement in both glucose tolerance
and insulin sensitivity (3, 4, 6). The helminth-mediated
modulation was associated with a concomitant increase in
eosinophil and ILC2 recruitment within the epididymal
white adipose tissue (E-WAT) of the mice and the release
of the type 2 cytokines IL-4, IL-5, and IL-13, resulting in
increased AAMs (3, 4, 6). Furthermore, injection of obese
mice with type 2-inducing Schistosoma egg-derived antigens
also improved metabolic homeostasis (6). Analysis of sol-
uble antigens in S.mansoni eggs identified the glycoprotein
S. mansoni egg-derived v1 (v1), a T2 RNase (7), as the
predominant type 2-inducing component (8, 9).
In this study, we sought to address the mechanisms
underlying type 2 modulation of obesity and metabolic
homeostasis using v1 as a type 2-inducing molecule.
Treatment of obese mice with v1 induced a potent type 2
cellular response in the adipose tissue, with associated re-
lease of IL-33 from adipocytes, stimulating cells within the
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peritoneal cavity and adipose tissue to release type 2 cyto-
kines, resulting in a localized accumulation of innate type2
cells in theE-WAT.Thiscapacityofv1to induceIL-33release
and modulate obesity is dependent upon the molecule’s
RNase activity. Data presented herein demonstrate a poten-
tial RNase-mediated mechanism for modulation of type 2
immunity by an IL-33–dependent ILC2-mediated mecha-
nism to alter obesity and stabilize glucose homeostasis.
MATERIALS AND METHODS
Animals
C57BL/6J, Cd2062/2, and Rorasg/sg mice were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA). T1/ST2-
deficient mice (Il1rl12/2) (10), IL-33 citrine reporter mice
(Il33Cit/+), and IL-33–deficient mice (Il33Cit/Cit) (11) were
crossed to C57BL/6J in-house. Conditional retinoic acid orphan
receptor (Ror)a floxed mice were generated, and Rorafl/sg were
crossed to Il7rCre (12), as previously described (13). Animals were
housed in a specific pathogen-free facility in individually venti-
lated and filtered cages under positive pressure. All animal ex-
periments were performed in compliance with the Irish Medi
cines Board regulations and approved by the Trinity College
Dublin’s BioResources ethical review board.
High-fat diet and in vivo metabolic testing
Age-matchedmice were fed a high-fat diet (60%kcal fat, D12492;
Research Diets, Inc., New Brunswick, NJ, USA) or control diet
(10% kcal fat) for 8–16 wk as indicated (14). Glucose tolerance
was assessed inmice unfed overnight and challenged with 2 g/kg
glucose i.p. Insulin tolerance was tested inmice unfed for 4 h and
challenged with 0.75mU/g human insulin i.p. Blood glucose was
measured at the times indicated using a glucometer (Abbott
Laboratories, Abbott Park, IL, USA).
S. mansoni egg antigen injection
S. mansoni eggs were isolated from the livers of infectedmice and
soluble egg antigens prepared as previously described (15). Na-
tivea1 andv1 were isolated from soluble egg antigens by column
chromatography, as previously described (16). Obese mice were
injected intraperitoneally with 25 mg native a1 (d 0, 2, and 4) or
25 mg native v1 (d 0, 2, and 4), and weight was monitored, as
indicated in the figure legend (Supplemental Fig. S1).
Recombinant v1 production
Recombinantv1, glycosylationmutantv1 (N71/176Q;v1DGLY),
and RNase mutant v1 (H58F; v1DRNase) were expressed with a
6xHis tag in human embryonic kidney 293 cells, as previously
described (8, 17). Recombinant v1, v1DGLY, and v1DRNase were
purified from culture supernatants by nickel-affinity and gel-
filtration chromatography. Purified protein was subject to de-
tergent endotoxin extraction with v1 preparations having ,0.5
EU/mg protein (Lonza, Walkersville, MD, USA). The resultant
proteins were checked for purity by SDS-PAGE.RNase activity was
checked by incubating recombinant v1 and v1DRNase (500 and
100 ng/ml, respectively) with 1 mg RNA isolated from murine
bonemarrow-derivedmacrophages for 1h at 37°C. RNA integrity
was determined by running on a 2% agarose gel and RNA visu-
alized using ethidiumbromide.Obesemicewere injectedwith 25
mg v1, v1DGLY, or v1DRNase i.p. on d 0, 2, and 4 and weight
monitored for 3 wk postinitial injection (Supplemental Fig. S2B).
Corresponding groups of mice were treated with 25 mg
endotoxin-free ovalbumin (OVA) as a glycoprotein control.
Histology
E-WAT frommicewas perfused andfixed in 10% formalin saline,
and then paraffin embedded. Paraffin-embedded sections were
cut to4mMand the slides stainedwithhematoxylinandeosin. For
uncoupling protein 1 (UCP1) staining, slides were deparaffinized,
and antigen retrieval was carried out by heating sections to 95°C in
sodiumcitratebuffer. Sectionswereblockedwithgoat serumbefore
incubation with rabbit anti-UCP1 antibody (ab10983; Abcam Inc.,
Cambridge, United Kingdom) diluted 1:100. Following peroxidase
blocking, horseradish peroxidase-conjugated goat anti-rabbit
(P0448; Dako, Glostrup, Denmark) was used as the secondary an-
tibody, and sectionswere incubatedat 1:1000 inPBS for 1h at room
temperature. For staining, diaminobenzidine chromagen (K3468;
Dako) was used according to the manufacturer’s instructions, and
Mayer’s hematoxylin was used to counterstain.
Murine cell culture and stimulation
Murine adipocytes andmacrophages were isolated from adipose
tissue after incubation with 1 mg/ml collagenase D from Clos-
tridium histolyticum (Roche Applied Science, Burgess Hill, United
Kingdom). Briefly, the E-WAT was collected, mechanically
shredded, and incubated with collagenase D at 37°C with gentle
shaking for1h.After centrifugationat400 g, the surfaceadipocyte
fraction was gently collected and washed 3 times in PBS supple-
mented with 10% fetal calf serum. Adipocytes were identified as
SSChiFSChiCD90+Sca-1+CD11b2 by flow cytometry. Macrophages
(F4/80+cells)werepreparedfromthestromalvascular fractionfrom
the E-WAT. Adipocytes and macrophages were cultured in Roswell
ParkMemorial Institutemedium(Buffalo, NY,USA) supplemented
with 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml strep-
tomycin at a density of 2 3 106 cells/ml for 24 h, and the culture
supernatant was discarded. Cells were incubated with 500 ng/ml
recombinant v1 for 1–24 h, as indicated in the figure legend (Fig.
4E). Culture supernatants were collected for cytokine profiling.
Serum triglyceride quantification
Serum was assessed for triglyceride levels using the Abnova tri-
glyceride quantification kit (Heidelberg, Germany) following the
manufacturer’s instructions.
Mouse cytokine ELISAs
Cytokine levels were quantified in tissue culture supernatants,
peritoneal lavage fluid samples, and serum. Samples were ana-
lyzed by sandwich ELISAs to quantify levels of specific cytokines.
IL-33 was measured with the DuoSet ELISA development system
from R&D Systems (Abingdon, United Kingdom) following the
manufacturer’s protocol.
Human adipocyte isolation
Adipocytes were isolated from omental adipose tissue biopsies
from obese patients (body mass index,50) undergoing elective
bariatric surgery. Clinical studies were approved by the St.
Vincent’sUniversityHospital, Dublin Ethics Committee.Written
informed consent was obtained from each participant before
commencement of research activities. Omental samples were
processed to isolate adipocytes as described above. Adipocytes
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were incubated with 500 ng/ml v1 for 3 and 24 h. IL-33 was
quantified in the culture supernatant by ELISA (R&D Systems).
Flow cytometry
E-WATfrom leanandobesemicewasmechanically shreddedand
incubated with 1 mg/ml collagenase D from C. histolyticum and a
single-cell suspensionprepared fromthestromalvascular fraction
(5). In addition, the adipocytes were collected and prepared for
flow cytometry. Surface marker expression was assessed by flow
cytometry with data collection on a CyAn (Beckman Coulter,
HighWycombe,United Kingdom), and datawere analyzed using
FlowJo software (Treestar, Ashland, OR, USA). IL-33 expression
was determined using Il33Cit/+ reporter mice. To identify ILC2s,
cells were stained with BD Biosciences (Oxford, United King-
dom) mAbs CD8-APC (Ly-2), B220-APC (RA3-6B2), F4/80-APC
(BM8), ICOS-PE (7E.17G9), and Siglec-F-APC (E50-2440);
eBioscience Incorporated (Hatfield, United Kingdom) mAbs
CD4-APC (RM4-5), CD11b-APC (M1/70), Gr-1-APC (RB6-8CS),
and FceR1-APC (MAR-1); and MD Biosciences (Zurich, Switzer-
land) mAb T1/ST2-FITC (DJ8). To identify eosinophils and
AAMs, cells were stained with BD Biosciences mAbs Siglec-F-PE
(E50-2440) and F4/80-APC (BM8), eBioscience Incorporated
mAb CD11b-PerCP (M1/70), and BioLegend (London, United
Kingdom) mAb CD206-PECy7 (C068C2). Prior to surface stain-
ing, all cells were incubated with Live/Dead Fixable Aqua stain
(Molecular Probes, Invitrogen, Dublin, Ireland) to isolate dead
cells. Using appropriate isotype controls, quadrants were drawn,
and data were plotted on logarithmic scale density plots.
RNA isolation and real-time PCR
RNAwas isolated fromhomogenizedE-WATusing theRNeasy kit
and reverse transcribedusing theQuantiTectReverseTranscription
Kit incorporating a genomic DNA elimination step (Qiagen, Ger-
mantown,MD,USA).Real-timequantitativePCRwasperformedon
an ABI Prism 7900HT sequence detection system (Applied Bio-
systems, Dublin, Ireland) using predesigned TaqMan gene expres-
sion assays specific for murine UCP1 (Mm01244861_m1) and
normalized tomurine glyceraldehyde 3-phosphate dehydrogenase.
Fold expression was calculated using the DDCtmethod of analysis.
Statistics
Statistical analysis was performed using GraphPad InStat
(GraphPad Software, La Jolla, CA,USA). Results are presented as
means 6 SEM. Differences, indicated as 2-tailed P values, were
considered significant when P . 0.05 as assessed by unpaired
Student’s t test with Welch correction applied as necessary.
RESULTS
S. mansoni egg-associated proteins induce weight loss
and promote glucose homeostasis in obese mice
Analysis of S. mansoni egg-excreted antigens has identified
2 major glycoproteins responsible for the immune-
modulating activity of eggs: v1 and S. mansoni egg-
derived a1 [a1/IPSE (a1)] (7, 18). Althoughv1 induces
type 2 responses (8, 9, 17),a1/IPSE can induce basophils
to produce IL-4, aiding a Th2 response (19). Intraperito-
neal injection of obese mice with 25 mg native v1, but not
a1, induces a transient significant (P , 0.05) delay in
weight gain (Supplemental Fig. S1A) and also significantly
(P, 0.05) improved glucose tolerance (Supplemental Fig.
S1B). These data indicate that when injected into obese
mice, the helminth glycoprotein v1, the major secreted
Th2-inducing glycoprotein in S. mansoni eggs, but not
a1/IPSE, can improve metabolic status.
To further address the immunologic mechanism un-
derlying the ability ofv1 tomodulateobesity, wegenerated
recombinant v1 from human embryonic kidney 293 cells
(Supplemental Fig. S2A). A dose of 25 mg v1 was admin-
istered by i.p. injection based on dose response and opti-
mal delivery route experiments (Supplemental Fig. S2C,
D). Treatment of obese mice with recombinant v1 given
intraperitoneally on d 0, 2, and 4 (Supplemental Fig. S2B)
caused a rapid and significant (P, 0.01–0.05) weight loss
relative to mice injected with OVA as a control glycopro-
tein, with peak weight loss on d 6 postinitial injection (Fig.
1A). In addition, there was a significant (P , 0.01–0.001)
decrease in adiposity, characterized by a decrease in the
weight of both E-WAT and inguinal WAT in v1-treated
obesemice (Fig. 1B). This was also reflected in a significant
(P, 0.01) reduction in adipocyte area of v1-treated obese
mice(Fig. 1C).Leanmice treatedwithv1hadnoalterations
in weight gain, and additionally, food and water intake was
comparablebetweenv1-orOVA-treated leanorobesemice
(data not shown). Analysis of the effects ofv1 onmetabolic
parameters demonstrated that v1 treatment significantly
(P, 0.01) lowered fasting blood glucose in obesemice to a
level comparable to mice fed a control diet (Fig. 1D), with
significant (P , 0.05) decreases in glucose tolerance (Fig.
1E), although there was no significant improvement in in-
sulin sensitivity (Fig. 1F). Consistent with the improvements
in metabolic function, there was a decrease in serum tri-
glyceride levels in obese mice treated with v1 (Fig. 1G).
v1 is a glycoprotein, and its action is partly mediated
through its binding to the mannose receptor (CD206) on
the cell surface (17). CD206 is expressed on both AAMs
and adipocytes in the E-WAT (Fig. 2A) of obese mice,
suggesting that v1 could act directly on such cells within
the adipose tissue. Indeed, when injected into obese mice
unable to signal via CD206 [Cd2062/2 (20)], v1 did not
cause weight loss (Fig. 2B). Furthermore, using recombi-
nant v1 with mutations in the sites responsible for glyco-
sylation (N71/176Q;v1DGLY), we showno effect on weight
gain (Fig. 2C). These data indicate that binding of v1 to
CD206 is essential for its capacity to induce weight loss and
alter the metabolic status of obese mice.
It has become apparent that the cellular composition of
the adipose tissue is also partly responsible for the meta-
bolic status of bothmice and humans (21). AlthoughWAT
is an effective energy store, brown or beige adipocytes are
responsible for regulating calorific expenditure, thus pre-
venting weight gain in mice and humans (22, 23). The
weight loss andmetabolic changes inv1-treatedmicewere
associated with an increase in the expression of UCP1, a
surrogatemarker for beiging ofWAT (24, 25), in theWAT
(Fig. 1I). Therefore, v1 improves metabolic function and
induces beige cells within the adipose tissue.
v1 induces localized type 2 cellular responses in the
E-WAT of obese mice
Several studies have shown that the induction of a type
2 response, either systemically by infection (3, 6) or by
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injection of an exogenous cytokine (5), can induce alter-
ations in the immune cell populations in the adipose tissue
of obese mice leading to improved glucose homeostasis.
Becausev1 is associatedwith the inductionof IL-4 and IL-5
(8, 9, 17), we analyzed changes in the immune cell profile
of theE-WAT inobesemice injectedwithv1at both6dand
21 d after initial treatment following intraperitoneal injec-
tionsond0, 2, and4 (d+2 andd+17, respectively). Inobese
mice injected with the control protein OVA, the cellularity
of the E-WAT was proinflammatory, with Th1 cells and
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Figure 1. Recombinant v1 induces weight loss and an improvement in glucose homeostasis in obese mice. A) Weight gain,
expressed as a percentage from starting weight, in WT mice on high-fat diet (HFD) for 8 wk and treated with 25 mg recombinant
v1, or 25 mg OVA i.p. on d 0, 2, and 4. Weight was monitored for 21 d. B) Weight of excised E-WAT and inguinal white adipose
tissue (I-WAT) in OVA- and v1-treated mice at 6 d postinitial injection. C) Immunohistochemistry depicts hematoxylin and eosin
staining of excised E-WAT from control diet (CD)-fed animals and HFD-fed animals treated with OVA or v1. E-WAT was excised
at d 6 postinitial injection. Adipocyte area was calculated from histologic slides. D–F ) Blood glucose was assessed basally in unfed
mice (D), and glucose tolerance was assessed after injection of 2 g/kg glucose i.p. at d 6 postinitial injection of v1 (E); insulin
tolerance was assessed in unfed mice after injection of 0.75 mU/g human insulin i.p. at d 6 postinitial injection of v1 (F). G)
Levels of triglyceride were determined in the serum of OVA- and v1-treated mice. H, I ) Ucp1 expression (H) and UCP1+ cells (I)
were determined in the E-WAT of OVA- and v1-treated mice by quantitative PCR and immunohistochemistry, respectively. GTT,
glucose tolerance test; ITT, insulin tolerance test. Data are representative of n = 6–8 6 SEM from 3 independent experimental
replicates. ns, not significant. *P , 0.05; **P , 0.01; ***P , 0.001; ****P , 0.0001. Scale bars, 50 mm (C, I).
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CAMs predominating (Fig. 3A, B). In contrast, injection
with v1 dampened the obese proinflammatory cell signa-
ture with a significant (P , 0.05) decrease within the
E-WAT of Th1 cells (Fig. 3A; Supplemental Fig. S3A)
and CAMs (Fig. 3B; Supplemental Fig. S3B). Conversely,
v1 increased Th2 and Treg cells (Fig. 3A and Supple-
mental Fig. S3A; P, 0.01), AAMs (Fig. 3B; Supplemental
Fig. S3B; P , 0.05), eosinophils (Fig. 3C; Supplemental
Fig. S3C;P,0.05), and ILC2s (Fig. 3D; Supplemental Fig.
S3D ; P, 0.001) in the E-WAT of obese mice. These data
demonstrate that the weight loss and downstream im-
provement in glucosemetabolism in response tov1 are
associated with an increase in eosinophils and ILC2s in
the WAT and with the induction of AAM polarization;
these are cellular changes in adipose tissue known to
impact onmetabolic status (3, 26). Furthermore, these
alterations in cellular composition can still be detected
in the adipose tissue 17 d after treatment has ceased;
although these cellular increases are no longer signif-
icant, these data do suggest that v1 has a sustained
beneficial effect on the cellular milieu in the E-WAT.
v1 induces the systemic and localized release of IL-33
Becausev1 inducespotent type 2 responses, the role of the
epithelial cell-derived type 2-promoting cytokines IL-33
and thymic stromal lymphopoietin was investigated. The
ability of IL-25 to drive ILC2s and type 2 NK T cells,
resulting in weight loss in obese mice, has been reported
(5), and IL-33 is also involved in maintaining glucose ho-
meostasis and promoting beiging ofWAT (25, 27). Inmice
injected with v1, whereas we do not observe significant
induction of IL-25 or thymic stromal lymphopoietin, IL-33
is released into the peritoneal cavity 3 h postinjection (Fig.
4A; data not shown). IL-33 is a member of the IL-1 super-
family, typically released by stromal cells, mast cells, and
dendritic cells (DCs) (28). Using an IL-33 reporter mouse
(11), we analyzed the cellular repertoire expressing IL-33
in the E-WAT. Although IL-33 expression was apparent in
both macrophages and DCs to a small extent, the primary
cellular source of IL-33 in the E-WAT was adipocyte
(SSChiFSChiCD90+Sca-1+CD11b2) (Fig. 4B). Analysis of
the kinetics of IL-33 expression demonstrates maximal
expression of IL-33 in adipocytes 24 h after injection ofv1,
whereas macrophages increase expression of IL-33 72 h
after treatment (Fig. 4C). Furthermore, in vitro stimulation
with v1 induced significant (P , 0.0001) IL-33 release
from adipocytes isolated from obese mice (Fig. 4D) and
humans (Fig. 4E).UsingCD206-deficientmice (Cd2062/2),
we show that CD206 expression on the adipocyte is re-
quired for IL-33 release following in vitro treatmentwithv1
(Fig. 4D). Interestingly, macrophages isolated from the
E-WAT from either wild-type (WT) or Cd2062/2mice do
not release significant levels of IL-33 in response to in vitro
culture with v1; although expression of IL-33 is increased
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A) CD206 expression on E-WAT adipocytes
(SSChiFSChiCD90+Sca-1+CD11b2) and AAMs
(CD11b+F4/80hi) was determined by flow
cytometry. B) Weight gain, expressed as a
percentage from starting weight, in WT
and CD206-deficient mice on high-fat diet
for 8 wk and treated with 25 mg v1, or
25 mg OVA i.p. on d 0, 2, and 4. C) Weight
gain, expressed as a percentage from starting
weight, in WT mice on high-fat diet for 8 wk
and treated with 25 mg v1 (WT), 25 mg
v1DGLY, or 25 mg OVA i.p. on d 0, 2, and
4. Max., maximum. Data are representa-
tive of n = 2–6 6 SEM from 2 independent
experimental replicates. ns, not significant.
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in these cells in vivo (Fig. 4C). The release of IL-33 from
cells is often associated with cell death. In accordance with
the cytotoxic nature of v1, we observe increased death
of peritoneal exudate cells in the peritoneal cavity fol-
lowing v1 treatment (Fig. 4E). Analysis of the IL-33–
expressing adipocytes demonstrated an increase in cell
death associated withv1 treatment (Fig. 4F). These data
suggest that the localized cytotoxicity of v1 induces
E-WAT adipocytes to increase production and release
of IL-33.
RNase activity of v1 induces weight loss and regulates
glucose homeostasis
v1 has been identified as a T2 RNase (7) (Supplemental
Fig. S2E), a property shown to be integral to the ability of
v1 to induce IL-4 and IL-5 release (17). A recombinant
v1 RNase-null (v1DRNase) mutant was generated, by
substituting a phenylalanine residue in the RNase cat-
alytic domain with a histidine residue (H58F), that was
devoid of RNase activity (Supplemental Fig. S2E).
Treating obese mice with v1DRNase did not induce sig-
nificant weight loss or a significant reduction in adi-
posity (Fig. 5A, B). Furthermore, v1DRNase did not
improve glucose tolerance in obese mice (Fig. 5C). The
absence of functional RNase activity also decreased type
2 cell infiltration into the E-WAT, with fewer ILC2s and
AAMs observed; although interestingly, eosinophil in-
filtration was still significantly (P, 0.001) increased (Fig.
5D). In contrast to the mutant v1DRNase protein,
recombinant v1 with RNase activity (Supplemental Fig.
S2E) was efficacious in modulating these parameters in
obese mice (Fig. 5A–D). Furthermore, RNase activity was
required for v1-elicited release of IL-33 into the perito-
neal cavity of mice (Fig. 5E) as well as inducing IL-33
expression in adipocytes (Fig. 5F). These data confirm a
role for the RNase activity of v1 in the induction of
metabolic changes and also demonstrate an RNase-
mediatedmechanism for the stimulation of the release of
IL-33.
Weight loss and type 2 cell induction by v1 are
dependent on IL-33
To formally validate a role for IL-33 in v1-mediated
weight loss, obese IL-33 receptor (IL-33R; T1/ST2)–
deficient (Il1rl12/2) and IL-33–deficient (Il33Cit/Cit)
mice were injected with v1. In the absence of IL-33 and
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IL-33–mediated signaling, v1 did not induce significant
weight loss in obese animals as compared toWT animals
(Fig. 6A). Furthermore, there was no alteration in glu-
cose tolerance in IL-33 pathway-deficient obese mice
treated with v1 (Fig. 6B). In support of v1-induced
weight loss and the changing cellularity of E-WAT being
IL-33 dependent, injection of v1 into obese IL-33– and
IL-33R–deficient mice did not significantly induce
ILC2s, eosinophils, or AAMs in the E-WAT (Fig. 6C).
Wenext investigated the identityof the IL-33–responsive
cells responsible for weight loss in the v1-treated mice.
IL-33 is a potent inducer of ILC2s in mice, and these cells
have been identified recently as playing important roles in
the activation and recruitment of eosinophils and AAMs in
the E-WAT (4, 25). ILC2s are reliant upon the transcription
factor RORa for their development, and staggerer mice
(Rorasg/sg), which have a natural mutation in the gene
encoding RORa, are specifically deficient in ILC2s (29).
To address the role of ILC2s in v1-induced weight loss,
ILC2-deficient Rorafl/sgIl7rCre mice were used (13).
These mice demonstrate a complete ablation of ILC2s
(Fig. 7A), in the context of this study we do not see
significant reductions in the basal levels in any other
cell population, however, the depletion of ILC2s can
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potentially impact CD4+ T cells, however, we do not
observe any associated decrease in CD4+ T cell pop-
ulations in the E-WAT [(13); data not shown]. Strikingly,
administration of v1 to obese Rorafl/sgIl7rCre mice dem-
onstrated that ablation of ILC2s prevented significant
weight loss, in contrast to the sustained weight loss in v1-
treated WT control Rorafl/+Il7rCre mice (Fig. 7A). Fur-
thermore, the ability of v1 to improve glucose tolerance
was ablated in mice deficient in ILC2s (Fig. 7A). In addi-
tion, in the absence of ILC2s, injection of obese mice with
v1 failed to induce infiltration of eosinophils and AAMs
into the E-WAT of obese mice (Fig. 7B). These data in-
dicate that v1 requires IL-33 and ILC2s to cause the al-
teration in the immunecellmilieu in theE-WAT, resulting
in increased eosinophilia and localized AAMpolarization,
which are associated with an improvement in metabolic
parameters.
DISCUSSION
Obesity and metabolic disorders are rapidly becoming an
epidemic and amajor cause of morbidity in the developed
world. Many studies have focused on the immunologic
causes of obesity and have associated the obese state with a
low-grade inflammatory response in the adipose tissue
(30). By promoting a more type 2 anti-inflammatory envi-
ronmentboth systemically and in theadipose tissue,weight
loss and an improvement in metabolic status can be
achieved (3–5, 24, 25). Data presented herein identify a
role for an isolated helminth egg-derived T2 RNase,v1, to
improve metabolic homeostasis in obese animals by a
mechanism dependent on driving IL-33 release and lo-
calized ILC2 recruitment.
Studies have previously used helminths as a method of
inducing a systemic type 2 response andhave demonstrated
favorable effects on metabolic parameters in mice
(3, 6). This return tometabolic homeostasis in helminth-
infected obese mice is associated with increased eosin-
ophils, ILC2s, and AAMs in the adipose tissue, a change
in immune status that can be maintained through
chronic infection (3, 6). This study provides mechanis-
tic insight into helminth modulation of obesity and
identifies a specific protein released by helminth eggs,
which is capable of driving a similar alteration in im-
mune andmetabolic parameters as that observed in live
helminth infection. Studies have focused on the ability
of v1 to drive DCs to polarize naive CD4 cells to a Th2
phenotype, via a mechanism requiring both glycosyla-
tion and RNase activity (17). Although glycosylation is
required for internalization ofv1 via binding to CD206,
the RNase interferes with protein synthesis by global
cleavage of rRNA and mRNA once translocated to the
cytosol, enablingv1 to conditionDCs for priming ofTh2
responses (17). The v1 RNase is not unique in its asso-
ciation with induction of a Th2 response; the birch
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pollen antigen Bet v-1 has been identified as an RNase
(31), and the fungal RNase Aspf-1 has allergenic ca-
pacity (32). These studies suggest that the ability to in-
duce a Th2 response via RNase activity may not be
unique to helminths.
The mechanisms described in this study identify a cen-
tral role for IL-33 in obesity and metabolic homeostasis.
Indeed, IL-33 is rapidly becoming accepted as an impor-
tant factor in limiting obesity and metabolic dysregulation
with several groups identifying a central role for IL-33 in
metabolism (25, 27, 33). We have shown that v1 is able
to drive IL-33 release from cells, in particular adipocytes,
through its intrinsic RNase activity. This v1-mediated
release of IL-33 not only alters the immune environment
within the adipose tissue but also promotes the beiging of
WAT, in a mechanism that limits adiposity by increasing
calorific expenditure (24). Furthermore, we have shown
that, in addition to immune cells within the WAT, adipo-
cytes themselves are a target forv1 andexpress and release
IL-33. This appears to bemediated via the RNase function
of the protein because IL-33 expression is ablated if the
RNase function of v1 is mutated. However, v1 is a hepato-
toxin (18, 34), and IL-33 release is often associated with
cellular necrosis (35). Indeed, we do observe localized cell
death in vitro in response to v1 treatment, although at
low levels. Furthermore, ,50% of the IL-33–expressing
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adipocytesaredying; therefore,whereascelldeath is likely to
be a mechanism inducing IL-33 and thus causing weight
loss, there is potentially another mechanism underlying
IL-33 release in response to v1.
IL-33 is an important inducer of ILC2, a cell widely im-
plicated in improvingmetabolic status in obese mice (4, 5,
25). Notably, we also observed thatv1-induced ILC2s were
required for weight loss and improving glucose tolerance.
However, due to the lack of CD206 on the surface of ILC2s
(36), it is unlikely thatv1 acts directly on ILC2s. Instead, we
propose a mechanism where v1 binding to CD206 on
adipocytes initially induces IL-33 release in part via an
RNase-mediated mechanism, thereby inducing ILC2s
and other innate cells to release IL-4, IL-5, and IL-13
resulting in a switch in polarization of macrophages to
AAMs (Fig. 8).
This study provides further mechanistic insight into
the immune-mediated regulation of obesity. We dem-
onstrate an important role for RNase-mediated IL-33
release in promoting metabolic homeostasis in obese
animals. We also identify the ability of v1 to induce IL-33
release from human adipocytes, suggesting that any
beneficial effect that v1 treatment has in mice has the
additional potential to be beneficial in humans. Data
presented herein not only provide novel mechanistic
insights into the roles of IL-33 and ILC2s in promoting
metabolic homeostasis, but they also raise the potential
beneficial therapeutic use of type 2-inducing RNases in
the treatment and management of obesity and obesity-
related metabolic disorders.
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